Metraipolis › archive › dc_7f6effbe68c4

The evolving landscape of first-line and subsequent therapies in EGFR-mutated NSCLC: efficacy, resistance, and tolerability — Europe PMC PMID:42079860

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42079860
DOI
10.37349/etat.2026.1002370
License (as archived)
solo-consultazione
Archived
2026-11-03T04:13:58.702Z
SHA-256 of the archived text
4cf9c9ee9464dd82afa1485d8d2923b61d06c313af1aa40bb0c29bc55fa02c4f
Stable URL of this page
https://metraipolis.com/documento/dc_7f6effbe68c4

How to cite

The evolving landscape of first-line and subsequent therapies in EGFR-mutated NSCLC: efficacy, resistance, and tolerability — Europe PMC PMID:42079860 — Europe PMC (en), https://europepmc.org/article/MED/42079860 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_7f6effbe68c4 (Metraipolis archive dc_7f6effbe68c4, sha256 4cf9c9ee9464dd82afa1485d8d2923b61d06c313af1aa40bb0c29bc55fa02c4f)
BibTeX
@misc{dc7f6effbe68c4,
  title = {The evolving landscape of first-line and subsequent therapies in EGFR-mutated NSCLC: efficacy, resistance, and tolerability — Europe PMC PMID:42079860},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42079860},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_7f6effbe68c4; sha256 4cf9c9ee9464dd82afa1485d8d2923b61d06c313af1aa40bb0c29bc55fa02c4f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42079860. Agents can read the archived copy with the MCP tool read_document.